Independent directory Public ClinicalTrials.gov records United States
Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 19, 2026, 6:13 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 49–72 of 580 matching trials from the live ClinicalTrials.gov search.
Conditions
Advanced Malignant Solid Neoplasm, Metastatic Carcinoma in the Liver, Metastatic Carcinoma in the Lung, Metastatic Malignant Neoplasm in the Thoracic Cavity, Metastatic Malignant Solid Neoplasm
Interventions
Anti-GITR Agonistic Monoclonal Antibody BMS-986156, Ipilimumab, Nivolumab, Stereotactic Body Radiation Therapy
Drug · Biological · Radiation
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
51 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2025
U.S. locations
1
States / cities
Houston, Texas
Conditions
Hormone Receptor Positive Breast Cancer, HER-2 Positive Breast Cancer
Interventions
Abemaciclib, Trastuzumab, Fulvestrant, Standard of Care Single Agent Chemotherapy
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years and older · Female only
Enrollment
237 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2023
U.S. locations
32
States / cities
Bakersfield, California • Fullerton, California • Los Angeles, California + 22 more
Conditions
Breast Neoplasms, Pancreatic Neoplasms
Interventions
nab-Paclitaxel, Nivolumab, Gemcitabine, Carboplatin
Drug
Lead sponsor
Celgene
Industry
Eligibility
18 Years and older
Enrollment
114 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2018
U.S. locations
15
States / cities
Sacramento, California • Santa Monica, California • New Haven, Connecticut + 11 more
Conditions
Metastatic Lung Non-Small Cell Carcinoma, Metastatic Malignant Neoplasm in the Brain, Stage IV Lung Cancer AJCC v8
Interventions
Bevacizumab, Biopsy Procedure, Biospecimen Collection, Computed Tomography, Magnetic Resonance Imaging, Osimertinib
Biological · Procedure · Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
5 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2027
U.S. locations
18
States / cities
Los Angeles, California • Pasadena, California • Sacramento, California + 11 more
Conditions
Basal Cell Carcinoma of the Skin, Eccrine Carcinoma of the Skin, Recurrent Adult Soft Tissue Sarcoma, Recurrent Melanoma, Recurrent Skin Cancer, Squamous Cell Carcinoma of the Skin, Stage III Adult Soft Tissue Sarcoma, Stage IIIB Melanoma, Stage IIIC Melanoma, Stage IV Adult Soft Tissue Sarcoma, Stage IV Melanoma
Interventions
isolated limb perfusion, melphalan, quality-of-life assessment
Drug · Procedure
Lead sponsor
Albert Einstein College of Medicine
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2014
U.S. locations
1
States / cities
The Bronx, New York
Conditions
Solid Tumors
Interventions
INCB161734, Placebo, Investigator's choice of chemotherapy
Drug
Lead sponsor
Incyte Corporation
Industry
Eligibility
18 Years and older
Enrollment
588 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2029
U.S. locations
69
States / cities
Birmingham, Alabama • Anchorage, Alaska • Chandler, Arizona + 55 more
Conditions
Metastatic Melanoma, Recurrent Ewing Sarcoma/Peripheral Primitive Neuroectodermal Tumor, Recurrent Hodgkin Lymphoma, Recurrent Malignant Solid Neoplasm, Recurrent Melanoma, Recurrent Neuroblastoma, Recurrent Non-Hodgkin Lymphoma, Recurrent Osteosarcoma, Recurrent Rhabdomyosarcoma, Refractory Ewing Sarcoma/Peripheral Primitive Neuroectodermal Tumor, Refractory Hodgkin Lymphoma, Refractory Malignant Solid Neoplasm, Refractory Melanoma, Refractory Neuroblastoma, Refractory Non-Hodgkin Lymphoma, Refractory Osteosarcoma, Refractory Rhabdomyosarcoma, Stage III Cutaneous Melanoma AJCC v7, Stage IIIA Cutaneous Melanoma AJCC v7, Stage IIIB Cutaneous Melanoma AJCC v7, Stage IIIC Cutaneous Melanoma AJCC v7, Stage IV Cutaneous Melanoma AJCC v6 and v7, Unresectable Melanoma
Interventions
Ipilimumab, Laboratory Biomarker Analysis, Nivolumab, Pharmacological Study
Biological · Other
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
12 Months to 30 Years
Enrollment
140 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2023
U.S. locations
24
States / cities
Birmingham, Alabama • Los Angeles, California • Orange, California + 21 more
Conditions
Castration Resistant Prostatic Cancer, Metastatic Prostate Cancer
Interventions
Pembrolizumab, Chemotherapy
Drug
Lead sponsor
University of California, San Francisco
Other
Eligibility
18 Years and older · Male only
Enrollment
26 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2023
U.S. locations
1
States / cities
San Francisco, California
Conditions
Non-Small Cell Lung Cancer
Interventions
Olaratumab, Paclitaxel, Carboplatin
Biological · Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years and older
Enrollment
137 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2017
U.S. locations
21
States / cities
Birmingham, Alabama • Bakersfield, California • Highland, California + 17 more
Conditions
Breast Cancer, Triple Negative Breast Cancer, PD-L1 Negative
Interventions
Sacituzumab Govitecan, Pembrolizumab
Drug
Lead sponsor
Dana-Farber Cancer Institute
Other
Eligibility
18 Years and older
Enrollment
110 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2029
U.S. locations
15
States / cities
Stamford, Connecticut • Miami, Florida • Plantation, Florida + 12 more
Conditions
Metastatic Melanoma, Skin Cancer
Interventions
Fludarabine, Cyclophosphamide, Aldesleukin, MART-1 Reactive CD8+ PBL
Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
5 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2014
U.S. locations
1
States / cities
Bethesda, Maryland
Conditions
Metastatic Cancer
Interventions
efaproxiral, radiation therapy
Drug · Radiation
Lead sponsor
Spectrum Pharmaceuticals, Inc
Industry
Eligibility
18 Years to 120 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2000 – 2003
U.S. locations
35
States / cities
Phoenix, Arizona • Tucson, Arizona • Berkeley, California + 28 more
Conditions
Colorectal Cancer
Interventions
panitumumab, erlotinib hydrochloride, irinotecan hydrochloride
Biological · Drug
Lead sponsor
Northwestern University
Other
Eligibility
18 Years and older
Enrollment
28 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2015
U.S. locations
10
States / cities
Arlington Heights, Illinois • Chicago, Illinois • Joliet, Illinois + 6 more
Conditions
Gastric Cancer
Interventions
Ramucirumab (IMC-1211B) DP, Placebo, Paclitaxel
Biological · Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years and older
Enrollment
665 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2017
U.S. locations
13
States / cities
Burbank, California • Los Angeles, California • San Francisco, California + 10 more
Conditions
Anemia, Graft Versus Host Disease, Leukemia, Lymphoma, Multiple Myeloma and Plasma Cell Neoplasm, Myelodysplastic Syndromes
Interventions
anti-thymocyte globulin, filgrastim, cyclophosphamide, thiotepa, allogeneic bone marrow transplantation, bone marrow ablation with stem cell support, radiation therapy
Biological · Drug · Procedure + 1 more
Lead sponsor
University of Maryland, Baltimore
Other
Eligibility
Up to 50 Years
Enrollment
45 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1998 – 2000
U.S. locations
1
States / cities
Baltimore, Maryland
Conditions
Bladder Cancer
Interventions
Durvalumab, Tremelimumab, Radiation Therapy
Drug · Radiation
Lead sponsor
Terence Friedlander, MD
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2024
U.S. locations
1
States / cities
San Francisco, California
Conditions
Soft Tissue Sarcomas
Interventions
Nivolumab, Pazopanib
Biological · Drug
Lead sponsor
NYU Langone Health
Other
Eligibility
18 Years to 100 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2022
U.S. locations
1
States / cities
New York, New York
Conditions
Metastatic Gastric Adenocarcinoma, Gastroesophageal Junction Adenocarcinoma
Interventions
Ramucirumab, Capecitabine, Cisplatin, Placebo, Fluorouracil
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years and older
Enrollment
645 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2020
U.S. locations
25
States / cities
Fayetteville, Arkansas • Bakersfield, California • Fullerton, California + 19 more
Conditions
Colorectal Cancer
Interventions
ALVAC-CEA-B7.1 vaccine, tetanus toxoid, FOLFIRI regimen, fluorouracil, irinotecan hydrochloride, leucovorin calcium
Biological · Drug
Lead sponsor
Herbert Irving Comprehensive Cancer Center
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2001
U.S. locations
10
States / cities
Birmingham, Alabama • Los Angeles, California • Washington D.C., District of Columbia + 6 more
Conditions
Anatomic Stage IV Breast Cancer AJCC v8, HER2-Negative Breast Carcinoma
Interventions
Biospecimen Collection, Computed Tomography, Gemcitabine, Magnetic Resonance Imaging, Naxitamab, Universal Donor Expanded TGF-beta-imprinted NK Cells
Procedure · Drug · Biological
Lead sponsor
Margaret Gatti-Mays
Other
Eligibility
18 Years and older
Enrollment
42 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
1
States / cities
Columbus, Ohio
Conditions
Metastatic Non-Small Cell Lung Cancer (NSCLC)
Interventions
Durvalumab, Danvatirsen, Oleclumab, MEDI5752, Pemetrexed, Carboplatin, Gemcitabine, Cisplatin, Nab-paclitaxel, AZD2936
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 130 Years
Enrollment
175 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2026
U.S. locations
3
States / cities
Iowa City, Iowa • Pittsburgh, Pennsylvania • Nashville, Tennessee
Conditions
Solid Neoplasm
Interventions
Laboratory Biomarker Analysis, Mitomycin, Veliparib
Other · Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2009
U.S. locations
2
States / cities
Georgetown, Kentucky • Columbus, Ohio
Conditions
Non-small Cell Lung Cancer
Interventions
Docetaxel, TAK-117
Drug
Lead sponsor
Millennium Pharmaceuticals, Inc.
Industry
Eligibility
18 Years and older
Enrollment
14 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2017
U.S. locations
6
States / cities
San Diego, California • Atlanta, Georgia • Farmington Hills, Michigan + 3 more
Conditions
Leukemia, Lymphoma, Multiple Myeloma and Plasma Cell Neoplasm, Myelodysplastic Syndromes, Precancerous Condition, Secondary Myelofibrosis
Interventions
Busulfan, Cytarabine, Fludarabine phosphate, mycophenolate mofetil, tacrolimus, allogeneic hematopoietic stem cell transplantation, umbilical cord blood transplantation, total-body irradiation
Drug · Procedure · Radiation
Lead sponsor
Barbara Ann Karmanos Cancer Institute
Other
Eligibility
Up to 69 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2015
U.S. locations
1
States / cities
Detroit, Michigan